WWW.DISSERTATION.XLIBX.INFO
FREE ELECTRONIC LIBRARY - Dissertations, online materials
 
<< HOME
CONTACTS



Pages:     | 1 |   ...   | 7 | 8 ||

«Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in ...»

-- [ Page 9 ] --

It should be noted that, while the maximum recommended dose for moderately depressed outpatients is also 225 mg/day for Effexor (immediate release), more severely depressed inpatients in one study of the development program for that product responded to a mean dose of 350 mg/day (range of 150 to 375 mg/day). Whether or not higher doses of Effexor XR are needed for more severely depressed patients is unknown; however, the experience with Effexor XR doses higher than 225 mg/day is very limited. (See PRECAUTIONS-General-Use in Patients with Concomitant Illness.) Generalized Anxiety Disorder For most patients, the recommended starting dose for Effexor XR is 75 mg/day, administered in a single dose. In clinical trials establishing the efficacy of Effexor XR in outpatients with Generalized Anxiety Disorder (GAD), the initial dose of venlafaxine was 75 mg/day. For some patients, it may be desirable to start at 37.5 mg/day for 4 to 7 days, to allow new patients to adjust to the medication before increasing to 75 mg/day. Although a dose-response relationship 45 Reference ID: 3537473 for effectiveness in GAD was not clearly established in fixed-dose studies, certain patients not responding to the initial 75 mg/day dose may benefit from dose increases to a maximum of approximately 225 mg/day. Dose increases should be in increments of up to 75 mg/day, as needed, and should be made at intervals of not less than 4 days. (See the Use in Patients with Concomitant Illness section of PRECAUTIONS.)

–  –  –

The recommended dose is 75 mg/day, administered in a single dose. There was no evidence that higher doses confer any additional benefit. (See the Use in Patients with Concomitant Illness

–  –  –

It is recommended that initial single doses of 37.5 mg/day of Effexor XR be used for 7 days. In clinical trials establishing the efficacy of Effexor XR in outpatients with panic disorder, initial doses of 37.5 mg/day for 7 days were followed by doses of 75 mg/day and subsequent weekly dose increases of 75 mg/day to a maximum dose of 225 mg/day. Although a dose-response relationship for effectiveness in patients with panic disorder was not clearly established in fixed-dose studies, certain patients not responding to 75 mg/day may benefit from dose increases to a maximum of approximately 225 mg/day. Dose increases should be in increments of up to 75 mg/day, as needed, and should be made at intervals of not less than 7 days. (See the Use in Patients with Concomitant Illness section of PRECAUTIONS.) Switching Patients from Effexor Tablets Depressed patients who are currently being treated at a therapeutic dose with Effexor (immediate release) may be switched to Effexor XR at the nearest equivalent dose (mg/day), eg, 37.5 mg venlafaxine two-times-a-day to 75 mg Effexor XR once daily. However, individual dosage adjustments may be necessary.

Switching a Patient To or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders: At least 14 days should elapse between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of therapy with Effexor XR.

Conversely, at least 7 days should be allowed after stopping Effexor XR before starting an MAOI intended to treat psychiatric disorders (see CONTRAINDICATIONS).

Use of Effexor XR With Other MAOls, Such as Linezolid or Methylene Blue: Do not start Effexor XR in a patient who is being treated with linezolid or intravenous methylene blue because there is increased risk of serotonin syndrome. In a patient who requires more urgent treatment of a psychiatric condition, other interventions, including hospitalization, should be considered (see CONTRAINDICATIONS).

In some cases, a patient already receiving therapy with Effexor XR may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, Effexor XR should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for symptoms of serotonin syndrome for 7 days or until 24 hours after the last dose of linezolid or intravenous methylene 46 Reference ID: 3537473 blue, whichever comes first. Therapy with Effexor XR may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue (see WARNINGS).

The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in intravenous doses much lower than 1 mg/kg with Effexor XR is unclear.

The clinician should, nevertheless, be aware of the possibility of emergent symptoms of serotonin syndrome with such use (see WARNINGS).

Special Populations Treatment of Pregnant Women During the Third Trimester Neonates exposed to Effexor XR, other SNRIs, or SSRIs, late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding (see PRECAUTIONS). When treating pregnant women with Effexor XR during the third trimester, the physician should carefully consider the potential risks and benefits of treatment.

Patients with Hepatic Impairment Given the decrease in clearance and increase in elimination half-life for both venlafaxine and ODV that is observed in patients with hepatic cirrhosis and mild and moderate hepatic impairment compared with normal subjects (see CLINICAL PHARMACOLOGY), it is recommended that the total daily dose be reduced by 50% in patients with mild to moderate hepatic impairment. Since there was much individual variability in clearance between subjects with cirrhosis, it may be necessary to reduce the dose even more than 50%, and individualization of dosing may be desirable in some patients.





Patients with Renal Impairment Given the decrease in clearance for venlafaxine and the increase in elimination half-life for both venlafaxine and ODV that is observed in patients with renal impairment (GFR = 10 to 70 mL/min) compared with normal subjects (see CLINICAL PHARMACOLOGY), it is recommended that the total daily dose be reduced by 25% to 50%.

In patients undergoing hemodialysis, it is recommended that the total daily dose be reduced by 50%. Because there was much individual variability in clearance between patients with renal impairment, individualization of dosage may be desirable in some patients.

Elderly Patients No dose adjustment is recommended for elderly patients solely on the basis of age. As with any drug for the treatment of major depressive disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, or panic disorder, however, caution should be exercised in treating the elderly.

When individualizing the dosage, extra care should be taken when increasing the dose.

Maintenance Treatment There is no body of evidence available from controlled trials to indicate how long patients with major depressive disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, or panic disorder, should be treated with Effexor XR.

It is generally agreed that acute episodes of major depressive disorder require several months or longer of sustained pharmacological therapy beyond response to the acute episode. In one study, 47 Reference ID: 3537473 in which patients responding during 8 weeks of acute treatment with Effexor XR were assigned randomly to placebo or to the same dose of Effexor XR (75, 150, or 225 mg/day, qAM) during 26 weeks of maintenance treatment as they had received during the acute stabilization phase, longer-term efficacy was demonstrated. A second longer-term study has demonstrated the efficacy of Effexor in maintaining a response in patients with recurrent major depressive disorder who had responded and continued to be improved during an initial 26 weeks of treatment and were then randomly assigned to placebo or Effexor for periods of up to 52 weeks on the same dose (100 to 200 mg/day, on a b.i.d. schedule) (see Clinical Trials under CLINICAL PHARMACOLOGY). Based on these limited data, it is not known whether or not the dose of Effexor/Effexor XR needed for maintenance treatment is identical to the dose needed to achieve an initial response. Patients should be periodically reassessed to determine the need for maintenance treatment and the appropriate dose for such treatment.

In patients with Generalized Anxiety Disorder, Effexor XR has been shown to be effective in 6-month clinical trials. The need for continuing medication in patients with GAD who improve with Effexor XR treatment should be periodically reassessed.

In patients with Social Anxiety Disorder, Effexor XR has been shown to be effective in a 6-month clinical trial. The need for continuing medication in patients with Social Anxiety Disorder who improve with Effexor XR treatment should be periodically reassessed.

In a study of panic disorder in which patients responding during 12 weeks of acute treatment with Effexor XR were assigned randomly to placebo or to the same dose of Effexor XR (75, 150, or 225 mg/day), patients continuing Effexor XR experienced a significantly longer time to relapse than patients randomized to placebo. The need for continuing medication in patients with panic disorder who improve with Effexor XR treatment should be periodically reassessed.

Discontinuing Effexor XR Symptoms associated with discontinuation of Effexor XR, other SNRIs, and SSRIs, have been reported (see PRECAUTIONS). Patients should be monitored for these symptoms when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate. In clinical trials with Effexor XR, tapering was achieved by reducing the daily dose by 75 mg at 1 week intervals. Individualization of tapering may be necessary.

HOW SUPPLIED

Effexor XR® (venlafaxine hydrochloride) extended-release capsules are available as follows:

37.5 mg, grey cap/peach body with and “Effexor XR” on the cap and “37.5” on the body.

–  –  –

48 Reference ID: 3537473 75 mg, peach cap and body with and “Effexor XR” on the cap and “75” on the body.

–  –  –

Read the Medication Guide that comes with EFFEXOR XR before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment. Talk with your healthcare provider if there is something you do not understand or want to learn more about.

–  –  –

This Medication Guide has been approved by the U.S. Food and Drug Administration for all antidepressants.

This product’s label may have been updated. For current full prescribing information, please visit www.pfizer.com

–  –  –

54 Reference ID: 3537473

Pages:     | 1 |   ...   | 7 | 8 ||


Similar works:

«Pandemic Influenza Preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits (PIP Framework) Questions and Answers September 2011 Contents: Page I. General 3 II. Advisory Group 4 III. Global Influenza Surveillance & Response System (GISRS) 6 IV. Pandemic Influenza Benefit Sharing 7 V. Partnership Contribution 7 VI. Standard Material Transfer Agreements 8 VII. Intellectual Property Rights 9 VIII. Influenza Virus Traceability Mechanism (IVTM) 10 This...»

«Bandolero Byers Guide A Guide to Bando Basics and Inspection The Cars The Bando has been carefully designed with safety in mind. Some areas of the car are designed to “crush” and absorb energy in an impact. This “crush” also makes the cars somewhat fragile. Be prepared to repair/replace body panels, bumpers, frame horns and occasionally a front or rear clip. If necessary the entire rear frame behind the drivers compartment can be replaced. The front frame area, aprox 2 feet forward of...»

«Your Benefit Guide State Vision Plan For Active Employees and Retirees Blue Cross Blue Shield of Michigan is a nonprofit corporation and independent licensee of the Blue Cross and Blue Shield Association. Welcome Welcome to your State Vision Plan, administered by Blue Cross Blue Shield of Michigan (BCBSM) under the direction of the Michigan Civil Service Commission (MCSC). The MCSC is responsible for implementing your vision benefits and future changes in benefits. BCBSM will provide certain...»

«Nordic journal of working life studies Volume 3 ❚ Number 3 ❚ August 2013 Habituating pain: Questioning pain and physical strain as inextricable conditions in the construction industry Jeppe Z. N. Ajslev1 ❚❚ Ph.D. fellow, Centre for Working Life Research, Roskilde University Henrik L. Lund ❚❚ Associate professor, Centre for Working Life Research, Roskilde University Jeppe L. Møller ❚❚ Ph.D. fellow, Centre for Working Life Research, Roskilde University Roger Persson ❚❚...»

«Once Upon a Time in Africa Stories of Wisdom and Joy Compiled by Joseph G. Healey Founded in 1970, Orbis Books endeavors to publish works that enlighten the mind, nourish the spirit, and challenge the conscience. The publishing arm of the Maryknoll Fathers and Brothers, Orbis seeks to explore the global dimensions of the Christian faith and mission, to invite dialogue with diverse cultures and religious traditions, and to serve the cause of reconciliation and peace. The books published reflect...»

«The Effect of Early Rearing Experience on Adult Reproductive Behavior in Captive Giant Pandas (Ailuropoda melanoleuca) and Spectacled Bears (Tremarctos ornatus) A Thesis Presented to The Academic Faculty by Pei Sun In Partial Fulfillment of the Requirements for the Degree Master of Science in Psychology Georgia Institute of Technology November 2004 The Effect of Early Rearing Experience on Adult Reproductive Behavior in Captive Giant Pandas (Ailuropoda melanoleuca) and Spectacled Bears...»

«ÉTUDES ROMANES DE BRNO 35, 1, 2014 SAMUEL BIDAUD SUR LES SIGNIFIES DES MOTS ITALIENS CHE ET COSA Introduction Si elle est aujourd’hui très largement utilisée dans la linguistique francophone, la psychomécanique du langage est reçue de façon inégale à l’étranger. Si l’on excepte les travaux de quelques linguistes comme Alvaro Rochetti, Louis Begioni, Alberto Martone, Alberto Manco, Roberto Silvi ou Sophie Saffi, et le fait que les Principes de linguistique théorique et Temps et...»

«Intentional Binding and the Sense of Agency: A review James W. Moore1,2 & Sukhvinder S. Obhi3,4 1. Department of Psychology, Goldsmiths, University of London, London, UK 2. Brain Mapping Unit, Department of Psychiatry, University of Cambridge, Cambridge, UK 3. Centre for Cognitive Neuroscience & Department of Psychology, Wilfrid Laurier University, Waterloo, Ontario, Canada 4. Institute of Cognitive Neuroscience, University College London, London, U.K. Correspondence: sobhi@wlu.ca PrePrint...»

«Université Pierre et Marie Curie Psychomotricité : Développement psychomoteur de l’enfant Première année 2003 2004 Nelly Thomas Mise à jour : 12 décembre 2002 2/37 Psychomotricité : Développement psychomoteur de l’enfant Nelly Thomas 2003 2004 Sommaire Sommaire Sommaire 3 Chapitre 1 : Le développement psychomoteur de l’enfant 7 Chapitre 2 : Les lois de développement psychomoteur 9 2.1 L’acquisition d’une fonction motrice 9 2.1.1 La myélinisation 9 2.1.2 L’établissement...»

«Copyright © The British Psychological Society Reproduction in any form (including the internet) is prohibited without prior permission from the Society 63 The British Psychological British Journal of Clinical Psychology (2006), 45, 63–82 Society q 2006 The British Psychological Society www.bpsjournals.co.uk There’s nothing more practical than a good theory: Integrating motivational interviewing and self-determination theory Maarten Vansteenkiste1* and Kennon M. Sheldon2 1 University of...»

«The Real Thing 1. The Taste Test There’s something very special about a school fair. It’s the excitement of the weeks building up to it, and all the work that the kids do in the classroom, painting posters and making signs. It’s the colour and the bustle of the day itself, and how it always seems to be sunny, and the fact that on school fair day all the rules about what you’re allowed to eat, and not to eat, go straight out the window, and you’re allowed to stuff yourself with toffee...»

«Citation: Fitton, Daniel, Read, Janet, Horton, Matthew, Little, Linda and Toth, Nicola (2012) Constructing the Cool Wall: A tool to explore teen meanings of cool. PsychNology, 10 (2). pp. 141-162. ISSN 1720-7525 Published by: PsychNology Journal URL: http://www.psychnology.org/File/PNJ10(2)/PSYCHNOLOGY_JOURNAL_10_2_FITTON. pdf This version was downloaded from Northumbria Research Link: http://nrl.northumbria.ac.uk/10922/ Northumbria University has developed Northumbria Research Link (NRL) to...»





 
<<  HOME   |    CONTACTS
2016 www.dissertation.xlibx.info - Dissertations, online materials

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.